share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Dar Zavain

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Dar Zavain

Recursion Pharmaceuticals | 4:持股變動聲明-董事 Dar Zavain
美股SEC公告 ·  07/03 16:41

Moomoo AI 已提取核心訊息

Dar Zavain, associated with Recursion Pharmaceuticals, Inc. [RXRX], completed a stock acquisition on July 1, 2024. The transaction involved a grant of 1,843 shares of Class A Common Stock at no cost. Following the transaction, Zavain's direct holdings in the company increased to a total of 103,996 shares. The grant is part of the company's stock-based compensation program and reflects the ongoing commitment to align the interests of its employees with those of shareholders.
Dar Zavain, associated with Recursion Pharmaceuticals, Inc. [RXRX], completed a stock acquisition on July 1, 2024. The transaction involved a grant of 1,843 shares of Class A Common Stock at no cost. Following the transaction, Zavain's direct holdings in the company increased to a total of 103,996 shares. The grant is part of the company's stock-based compensation program and reflects the ongoing commitment to align the interests of its employees with those of shareholders.
與遞歸醫藥公司[RXRX]有關的Dar Zavain在2024年7月1日完成了股票收購交易。該交易涉及免費授予1,843股A類普通股。交易後,Zavain在該公司的直接持股總數增至103,996股。該授予是公司股權激勵計劃的一部分,反映了將員工利益與股東利益對齊的持續承諾。
與遞歸醫藥公司[RXRX]有關的Dar Zavain在2024年7月1日完成了股票收購交易。該交易涉及免費授予1,843股A類普通股。交易後,Zavain在該公司的直接持股總數增至103,996股。該授予是公司股權激勵計劃的一部分,反映了將員工利益與股東利益對齊的持續承諾。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息